Glenmark Pharmaceuticals Inc., USA to launch Eribulin Mesylate Injection, 1mg/2Ml (0.5 mg/mL) Single-Dose Vials

Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the upcoming launch1 of Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials. Glenmark's Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven®2 Injection, 1 mg/2 mL (0.5 mg/mL), of Eisai, Inc., and the company will begin distribution in September 2025.

According to IQVIA® sales data for the 12-month period ending July 2025, the Halaven® Injection, 1 mg/2 mL (0.5 mg/mL) market3 achieved annual sales of approximately $66.3 million*.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, "We are pleased to announce the launch of Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials. As the first complex generic in our portfolio, this launch marks both our commitment to growing our portfolio of products within the institutional channel and reinforces our dedication to bring quality and affordable alternatives to market for patients in need."

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 1928.20 as compared to the previous close of Rs. 1924.25. The total number of shares traded during the day was 9014 in over 1623 trades.

The stock hit an intraday high of Rs. 1938.20 and intraday low of 1903.50. The net turnover during the day was Rs. 17318516.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 EribulinMesylateInjection USA